Network Pharmacology Reveals SFI’s Anti-Glioma Mechanisms via SRC/PI3K/AKT

Study Background and Research Question

Gliomas represent some of the most aggressive and treatment-resistant primary brain tumors, accounting for 30–50% of such malignancies and carrying a generally poor prognosis despite advances in surgery, radiotherapy, and chemotherapy. Median survival for glioma patients remains under 17 months, underscoring the urgent need for novel therapeutic strategies. Traditional Chinese medicine formulations, including Shenqi Fuzheng injection (SFI)—a combination of Codonopsis pilosula (Franch.) Nannf. and Astragalus membranaceus (Fisch.) Bunge—have been used in the clinic as adjuncts to cancer therapy, but the molecular mechanisms underlying their anti-glioma effects remain incompletely understood. This study addresses the critical question: How does SFI inhibit glioma proliferation and migration at the molecular level, and which cellular pathways are involved?

Key Innovation from the Reference Study

The principal innovation of this investigation lies in its comprehensive application of network pharmacology—integrating computational prediction, in vitro cellular assays, and in vivo mouse models—to delineate the molecular targets of SFI in glioma. Unlike conventional reductionist approaches that focus on single targets, network pharmacology enables mapping of the complex, multi-component interactions inherent to herbal formulations. This study identifies the SRC/PI3K/AKT signaling pathway as a central node mediating SFI’s anti-glioma effects, providing mechanistic clarity and highlighting actionable molecular targets for future anti-angiogenic and anti-metastatic compound development (reference study).

Methods and Experimental Design Insights

The study employed a multi-pronged approach:

• Network Pharmacology: The researchers first catalogued putative targets of SFI’s components using databases and literature mining, identifying 110 SFI-associated targets and 3,343 glioma-relevant genes. Seventy-nine overlapping targets were mapped, suggesting direct intersections between SFI action and glioma biology.
• In Vitro Assays: Human glioma cell lines U87 and T98G were treated with SFI. Cell proliferation was quantified using CCK-8 and EdU incorporation assays. Clonogenic, wound healing, and Transwell migration assays evaluated proliferative and migratory potential. Cell cycle analysis was conducted by flow cytometry, and Western blotting assessed pathway modulation.
• In Vivo Validation: A C57BL/6 mouse subcutaneous glioma model (GL261 cells) was used to assess the translational impact of SFI. Tumor volume, histopathology (HE staining), and immunohistochemical markers probed for effects on tumor growth and pathway activity.

This design enables both broad target prediction and rigorous experimental confirmation, strengthening the mechanistic conclusions.

Core Findings and Why They Matter

The study reports several important findings:

• Inhibition of Proliferation and Migration: SFI significantly reduced proliferation and migration in U87 and T98G glioma cell lines, as demonstrated by decreased EdU positivity, reduced colony formation, and impaired wound closure and invasion (reference study).
• Cell Cycle Arrest: SFI induced S-phase arrest in glioma cells, as evidenced by flow cytometric analysis, suggesting a block in DNA synthesis and cell division.
• Suppression of Epithelial-Mesenchymal Transition (EMT): Markers of EMT, a key process in tumor metastasis, were downregulated upon SFI treatment, indicating reduced invasive potential.
• In Vivo Tumor Growth Suppression: SFI-treated mice exhibited significantly smaller tumors and reduced proliferation indices, corroborating the in vitro findings.
• Molecular Pathway Involvement: Network enrichment and experimental validation converge on the SRC/PI3K/AKT pathway as the principal axis modulated by SFI. This pathway is implicated in cell survival, proliferation, angiogenesis, and migration, and is frequently dysregulated in gliomas. The study’s mechanistic focus positions SFI as a multi-target angiogenesis inhibitor with potential application in tumor angiogenesis research.

These findings not only clarify the molecular underpinnings of SFI’s anti-glioma effects but also articulate new preclinical models for anti-angiogenic compound development.

Comparison with Existing Internal Articles

Recent internal reviews, such as "Network Pharmacology Reveals SFI Inhibits Glioma via SRC/PI3K/AKT", corroborate the centrality of the SRC/PI3K/AKT pathway in SFI’s mechanism, aligning network pharmacology results with both in vitro and in vivo validation. Similarly, another internal synthesis highlights the strategic value of targeting this pathway for anti-glioma therapy development. These resources reinforce the robustness of the reference study’s findings and provide additional protocol and workflow perspectives for researchers designing anti-angiogenic or EMT-inhibitory assays. In the context of VEGF receptor inhibitor research, articles such as "AAL-993: Next-Generation VEGF Receptor Inhibitor for Angiogenesis Research" discuss the practical design of angiogenesis assays, underscoring the importance of selectivity and pathway specificity, which are also central concerns in SFI-driven anti-angiogenic research. This points to a convergence of herbal pharmacology and small-molecule inhibitor strategies in the quest to modulate tumor angiogenesis with high precision.

Limitations and Transferability

Despite its strengths, the study has several limitations:

• Complexity of Herbal Formulations: The multi-component nature of SFI complicates the precise attribution of effects to individual compounds. While network pharmacology helps prioritize targets, the possibility of synergistic or antagonistic interactions remains.
• Model Constraints: The in vitro and subcutaneous tumor models, while informative, may not fully recapitulate the heterogeneous and immunosuppressive microenvironment of human gliomas.
• Pathway Breadth: Although the SRC/PI3K/AKT pathway is robustly implicated, SFI likely acts via additional mechanisms not exhaustively explored here.

Transferability to other tumor types or clinical settings will therefore require further validation, ideally incorporating orthotopic glioma models, patient-derived xenografts, and expanded molecular profiling.

Protocol Parameters

• Cell line selection: U87, T98G, and GL261 glioma cells are recommended for in vitro and in vivo assessment of anti-angiogenic and anti-proliferative effects.
• SFI treatment: Use concentration gradients (e.g., 0.5–2 mg/mL) to define dose-response relationships in CCK-8, EdU, and migration assays.
• Cell cycle analysis: After 24–48 hours of SFI exposure, use PI staining and flow cytometry to assess S-phase arrest.
• Pathway validation: Western blot for SRC, PI3K, AKT, and EMT markers (e.g., E-cadherin, N-cadherin, vimentin) is recommended for mechanistic studies.
• In vivo dosing: Initiate SFI administration upon tumor establishment in mouse models, with endpoint analysis by HE staining and immunohistochemistry for proliferation indices.

Research Support Resources

For researchers aiming to translate these mechanistic insights into anti-angiogenic compound screening, potent and selective VEGF receptor inhibitors such as AAL-993 (SKU C3730) from APExBIO can be integrated into similar tumor angiogenesis research workflows. AAL-993 offers high selectivity for VEGFR-1, VEGFR-2, and VEGFR-3, enabling the modeling of angiogenesis inhibition in both cellular and in vivo systems. For detailed assay design and mechanistic comparisons, see the internal article "AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angiogenesis". As always, AAL-993 is intended for research use only and should be handled according to established laboratory protocols.